Day: May 8, 2025

BELVIDERE, NJ, May 08, 2025 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, announced today that it will host a conference call on Thursday, May 15, 2025, at 8:00 AM Eastern Time to discuss financial results for the 2025 first quarter and provide a business update. The conference call will be available via telephone by dialing toll-free +1 877-545-0523 for U.S. callers or +1 973-528-0016 for international callers and entering access code 336637. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2914/52448 or on the investor relations section of the company’s website, https://ediblegardenag.com/presentations/. A webcast replay...

HAUPPAUGE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) — United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the first quarter of 2025. First quarter sales decreased from $3,254,944 in 2024 to $2,481,127 in 2025, with net income decreasing from $925,442 ($0.20 per share) to $560,895 ($0.12 per share). Donna Vigilante, President of United-Guardian, stated, “We are experiencing a slow start to 2025 compared to the beginning of 2024. While we saw positive performance from our medical lubricant and pharmaceutical businesses, the main reason for the decrease in sales and earnings was due to a decrease in our cosmetic ingredient business. Medical lubricant and pharmaceutical sales increased in the first quarter of 2025 compared to the same period in 2024 by 43% and 23%, respectively. Cosmetic ingredients sales decreased...

LiveWorld looks to increase its AI investment CAMPBELL, Calif. and NEW YORK , May 08, 2025 (GLOBE NEWSWIRE) — LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for first quarter 2025. Three Months 2025 Financial and Business HighlightsTotal three months revenues of $2.6 million Healthcare revenues of $2.3 million in Q1 2025 Net loss from operations of $276,000 a reduction of 45% when compared to 2024 Net Cash decreased by $1.6 million to $5.0 million from December 31, 2024Management Commentary “In the first quarter of the 2025 our total revenues were relatively flat when comparing 2024 to 2025, as both were approximately $2.6 million for the period, reflecting continued client concerns with the economy,” commented David Houston, Chief Financial Officer of LiveWorld. “For the rest of 2025 we will continue...

– Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study – – Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study interim data readout is expected in Q4 2025 – – Cash on hand of $17.5M provides operational runway through Q1 2026 – ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the first quarter ended March 31, 2025. “There are no FDA approved treatments to manage the neuropathic pain often resulting from chemotherapy treatment,” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. “We believe Halneuron’s®...

Qualstar Delivers Earnings of $0.13 Per Share IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Qualstar Corporation (OTC Markets: QBAK), a leading manufacturer of data storage solutions and high-efficiency power supply solutions, today announced its financial results for the three months ended March 31, 2025. Consolidated Financial Results (Unaudited) (Amounts in thousands except per share data and percentages)  Three Months Ended March 31,    2025    2024    $ ∆   % ∆                                 Revenues $ 1,659     $ 2,287     $ (628 )   (27.5 )%  Gross profit $ 609     $ 700     $ (91 )   (13.0 )%  Gross margin   36.7 %     30.6 %                                               Income (loss) from operations $ 135     $ (195 )                                               Net income (loss) $ 183     $ (100 )                                               Earnings...

LAS VEGAS, May 08, 2025 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE) (“Live Ventures” or the “Company”), a diversified holding company, today announced financial results for its fiscal second quarter 2025 ended March 31, 2025.  Fiscal Second Quarter 2025 Key Highlights:Revenue was $107.0 million, compared to $118.6 million in the prior year period Operating income increased $2.9 million to $2.1 million, compared to an operating loss of $0.8 million in the prior year period Successfully negotiated a $19 million reduction on the balance owed under the Flooring Liquidators, Inc. (“Flooring Liquidators”) seller note, which, when including the cancellation of accrued interest and other items, resulted in a $22.8 million net gain for Live Ventures Income before provision for income taxes was $21.1 million, compared...

First Quarter Highlights – 2025 vs. 2024Verification and certification revenue $4.2 million vs. $4.4 million Product sales flat at $0.7 million Total revenue $5.3 million vs. $5.6 million Net income $31,000 vs. $178,000 Diluted EPS $0.01 vs. $0.03 Company bought back 31,345 shares of its common stock at a cost of $383,000CASTLE ROCK, Colo., May 08, 2025 (GLOBE NEWSWIRE) — Where Food Comes From, Inc. (WFCF) (Nasdaq: WFCF), the most trusted resource for independent, third-party verification of food production practices in North America, today announced financial results for its first quarter ended March 31, 2025. “Our beef verification business, which represents approximately one-half of revenue mix, continued to feel the effects of smaller herd sizes and record high beef prices,” said John Saunders, CEO. “In addition, beef exports...

Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20Company will not pursue U.S. registrational path in gastric cancer following receipt of FDA feedback that accelerated approval pathway is not feasible based on ASPEN-06 due to standard-of-care evolving to ENHERTU®Data milestones expected across Company’s three clinical programs in 2026Cash runway has been extended into Q4 2026SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE...